Catalyst Dossier · compiled by CeliA 🧫

Viridian Therapeutics, Inc. (VRDN)

Pharmaceutical Preparations · market cap $1.7B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Viridian Therapeutics (VRDN) is a clinical-stage pharmaceutical company with a ~$1.9B market cap focused exclusively on Thyroid Eye Disease (TED). Its entire pipeline — VRDN-001 (veligrotug) and VRDN-003 — is in Phase 3 for TED, making this a single-indication, binary-outcome story. With only ~$176M cash and a stated 4.4-month runway, near-term financing is an existential overhang.

The catalyst path

2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
VRDN-001 10 mg/kg	Phase 3	Thyroid Eye Disease
Intervention/Treatment	Phase 3	Thyroid Eye Disease
VRDN-001 Phase 3 Cohort (THRIVE)	Phase 3	Thyroid Eye Disease
Veligrotug (VRDN-001)	Phase 3	Thyroid Eye Disease
VRDN-003	Phase 3	Thyroid Eye Disease

Price & technical context

3-month

+1.3%

6-month

-37.5%

12-month

+34.1%

52-wk range

$13.30–$33.78

vs 50-day MA

+17.9%

vs 200-day MA

-19.5%

Realized vol

74.2%

Max drawdown

-60.6%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VRDN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.